Certara (NASDAQ:CERT) Issues FY24 Earnings Guidance

by · The Cerbat Gem

Certara (NASDAQ:CERT – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.41-0.44 for the period, compared to the consensus EPS estimate of $0.41. The company issued revenue guidance of $380-385 million, compared to the consensus revenue estimate of $386.66 million. Certara also updated its FY 2024 guidance to 0.410-0.440 EPS.

Analysts Set New Price Targets

CERT has been the topic of several research analyst reports. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday, September 27th. Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Barclays dropped their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Certara presently has a consensus rating of “Hold” and a consensus price target of $15.92.

View Our Latest Research Report on Certara

Certara Trading Up 0.4 %

CERT stock traded up $0.04 during midday trading on Friday, hitting $11.03. 1,081,810 shares of the company’s stock were exchanged, compared to its average volume of 786,430. Certara has a 1-year low of $9.99 and a 1-year high of $19.87. The business has a 50-day simple moving average of $11.02 and a two-hundred day simple moving average of $13.70. The stock has a market capitalization of $1.77 billion, a PE ratio of -22.06, a P/E/G ratio of 4.88 and a beta of 1.51. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. During the same period in the previous year, the firm posted $0.06 earnings per share. The company’s revenue was up 10.7% on a year-over-year basis. On average, sell-side analysts predict that Certara will post 0.27 EPS for the current fiscal year.

Insider Activity

In other news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Company Profile

(Get Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Further Reading